May 15, 2017
Sumitomo Dainippon Pharma chalked up record sales and operating profit in the year ended March 2017 thanks to buoyant growth of its atypical antipsychotic Latuda (lurasidone) in North America, despite its sluggish performance in Japan. In FY2016, the Japanese drug...read more